Trials / Recruiting
RecruitingNCT07290036
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
An Open-label, Randomized, Parallel-group, Noninferiority Study to Evaluate the Pharmacokinetics of Bimekizumab Administered Intravenously or as a Subcutaneous Injection in Participants With Active Psoriatic Arthritis and/or Active Axial Spondyloarthritis
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 392 (estimated)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimekizumab regimen 1 iv | Participants will receive bimekizumab (BKZ) at pre-specified time points. |
| DRUG | Bimekizumab regimen 2 iv | Participants will receive bimekizumab (BKZ) at pre-specified time points. |
| DRUG | Bimekizumab regimen 3 sc | Participants will receive bimekizumab (BKZ) at pre-specified time points. |
Timeline
- Start date
- 2025-12-10
- Primary completion
- 2028-05-18
- Completion
- 2028-09-14
- First posted
- 2025-12-17
- Last updated
- 2026-04-13
Locations
25 sites across 4 countries: United States, Bulgaria, Germany, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07290036. Inclusion in this directory is not an endorsement.